HUP0304093A3 - Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them - Google Patents

Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them

Info

Publication number
HUP0304093A3
HUP0304093A3 HU0304093A HUP0304093A HUP0304093A3 HU P0304093 A3 HUP0304093 A3 HU P0304093A3 HU 0304093 A HU0304093 A HU 0304093A HU P0304093 A HUP0304093 A HU P0304093A HU P0304093 A3 HUP0304093 A3 HU P0304093A3
Authority
HU
Hungary
Prior art keywords
antineoplastic
pharmaceutical compositions
mtor inhibitor
antimetabolic
compositions containing
Prior art date
Application number
HU0304093A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HUP0304093A2 publication Critical patent/HUP0304093A2/hu
Publication of HUP0304093A3 publication Critical patent/HUP0304093A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0304093A 2001-04-06 2002-04-05 Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them HUP0304093A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28238801P 2001-04-06 2001-04-06
US28238501P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (2)

Publication Number Publication Date
HUP0304093A2 HUP0304093A2 (hu) 2004-04-28
HUP0304093A3 true HUP0304093A3 (en) 2008-08-28

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0304093A HUP0304093A3 (en) 2001-04-06 2002-04-05 Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them

Country Status (21)

Country Link
EP (1) EP1385551B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004525950A (cg-RX-API-DMAC7.html)
KR (1) KR100862178B1 (cg-RX-API-DMAC7.html)
CN (1) CN1309421C (cg-RX-API-DMAC7.html)
AT (1) ATE406892T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007242958A1 (cg-RX-API-DMAC7.html)
BR (1) BR0208627A (cg-RX-API-DMAC7.html)
CA (1) CA2442849A1 (cg-RX-API-DMAC7.html)
DE (1) DE60228699D1 (cg-RX-API-DMAC7.html)
EA (1) EA010184B1 (cg-RX-API-DMAC7.html)
ES (1) ES2312568T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0304093A3 (cg-RX-API-DMAC7.html)
IL (1) IL157898A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009092A (cg-RX-API-DMAC7.html)
NO (1) NO20034433L (cg-RX-API-DMAC7.html)
NZ (1) NZ540047A (cg-RX-API-DMAC7.html)
PL (1) PL363991A1 (cg-RX-API-DMAC7.html)
PT (1) PT1385551E (cg-RX-API-DMAC7.html)
SG (1) SG152906A1 (cg-RX-API-DMAC7.html)
SI (1) SI1385551T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002080975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
CZ309178B6 (cs) 2001-02-19 2022-04-20 Novartis Pharma Ag 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
PE20070763A1 (es) * 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
EP2662082A1 (en) * 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2629245C (en) * 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
BRPI0706528A2 (pt) * 2006-01-12 2011-03-29 Novartis Ag combinação de inibidor de mtor e composto antifolato
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
JP5372737B2 (ja) 2006-03-13 2013-12-18 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
AU2007252506C1 (en) 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
US20080161335A1 (en) 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
RU2483714C2 (ru) * 2007-03-07 2013-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
IL273579B2 (en) 2017-09-27 2025-10-01 Incyte Corp Salts of pyrrolizidine derivatives used as Tm inhibitors.
HRP20250676T1 (hr) 2018-06-29 2025-08-01 Incyte Corporation Formulacije inhibitora axl/mer
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
NZ336676A (en) * 1997-01-24 2000-01-28 Norsk Hydro As Gemcitabine esters or amides useful as anti-cancer and anti-viral agents
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
DE60228699D1 (de) 2008-10-16
ATE406892T1 (de) 2008-09-15
CN1545419A (zh) 2004-11-10
NO20034433L (no) 2003-11-25
NO20034433D0 (no) 2003-10-03
KR100862178B1 (ko) 2008-10-09
EP1385551B1 (en) 2008-09-03
ES2312568T3 (es) 2009-03-01
EA010184B1 (ru) 2008-06-30
CN1309421C (zh) 2007-04-11
CA2442849A1 (en) 2002-10-17
HK1060062A1 (en) 2004-07-30
BR0208627A (pt) 2004-03-09
SG152906A1 (en) 2009-06-29
PT1385551E (pt) 2008-11-03
WO2002080975A1 (en) 2002-10-17
HUP0304093A2 (hu) 2004-04-28
IL157898A0 (en) 2004-03-28
JP2004525950A (ja) 2004-08-26
PL363991A1 (en) 2004-11-29
AU2007242958A1 (en) 2008-01-10
KR20040007491A (ko) 2004-01-24
EA200301091A1 (ru) 2004-02-26
NZ540047A (en) 2007-01-26
MXPA03009092A (es) 2004-02-12
EP1385551A1 (en) 2004-02-04
SI1385551T1 (sl) 2008-12-31

Similar Documents

Publication Publication Date Title
HUP0304093A3 (en) Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
HUP0400114A3 (en) N-benzoyl-benzenesulfonamid derivatives as antitumor agents and pharmaceutical compositions containing them
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
GB0102342D0 (en) Pharmaceutical formulation
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
PT1461039E (pt) Composições farmacêuticas compreendendo cilostazol e um inibidor da captação de adenosina
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUS1400025I1 (hu) Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
GB0118689D0 (en) Pharmaceutical formulation
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
PL366432A1 (en) Pharmaceutical formulation
IL159591A0 (en) Pharmaceutical compositions containing terbinafin and use thereof
IL158236A0 (en) Pharmaceutical compositions containing azithromycin and derivatives thereof
GB0108470D0 (en) Pharmaceutical compositions and their use
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU2002254455A1 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
HUP0300557A3 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees